March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label ... specific responses in the nasal cavity following oral administration ...

Conducted on fully differentiated human nasal tissue using the MucilAir™ model, the study demonstrated ... is intended to remain in the nasal cavity for approximately 4 hours post-application.

Conducted on fully differentiated human nasal tissue using the MucilAirTM model, the study demonstrated ... is intended to remain in the nasal cavity for approximately 4 hours post-application.

Conducted on fully differentiated human nasal tissue using the MucilAir™ model, the study demonstrated strong local ... PL-14 Allergy Blocker is intended to remain in the nasal cavity for ...

His overuse of the product had resulted in a condition called rebound congestion syndrome, caused by inflammation of the moist inner lining of the nasal cavity. Decongestant sprays work by ...